TY  - JOUR

T1  - Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF)

JO  - Circulation

PY  - 2022/07/26

AU  - Lee MMY

AU  - Gillis KA

AU  - Brooksbank KJM

AU  - Allwood-Spiers S

AU  - Hall Barrientos P

AU  - Wetherall K

AU  - Roditi G

AU  - AlHummiany B

AU  - Berry C

AU  - Campbell RT

AU  - Chong V et al

ED  - 

DO  - DOI: 10.1161/circulationaha.122.059851

PB  - Ovid Technologies (Wolters Kluwer Health)

VL  - 146

IS  - 4

SP  - 364

EP  - 367

Y2  - 2024/12/22

ER  -